Vistagen Therapeutics, Inc. financial data

Symbol
VTGN on Nasdaq
Location
343 Allerton Avenue, South San Francisco, CA
Fiscal year end
March 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 675 % -66.1%
Debt-to-equity 18.9 % +132%
Return On Equity -90.7 % -149%
Return On Assets -76.3 % -127%
Operating Margin 26.1K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.5M shares +41.8%
Entity Public Float 81.2M USD +29.5%
Common Stock, Value, Issued 39K USD +44.4%
Weighted Average Number of Shares Outstanding, Basic 35.7M shares +16.7%
Weighted Average Number of Shares Outstanding, Diluted 35.7M shares +16.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues -227K USD -120%
Research and Development Expense 49.1M USD +64.6%
General and Administrative Expense 17.1M USD +2.69%
Operating Income (Loss) -65.5M USD -43.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -62.2M USD -57.3%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -62.2M USD -57.3%
Earnings Per Share, Basic -1 USD/shares -177%
Earnings Per Share, Diluted -1 USD/shares -177%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 62.8M USD -25.5%
Cash, Cash Equivalents, and Short-term Investments 77.2M USD -20.9%
Assets, Current 78.9M USD -21%
Property, Plant and Equipment, Net 516K USD +10.5%
Operating Lease, Right-of-Use Asset 1.07M USD -32.2%
Other Assets, Noncurrent 405K USD -18.7%
Assets 80.9M USD -21%
Accounts Payable, Current 1.83M USD +156%
Employee-related Liabilities, Current 3.36M USD +108%
Accrued Liabilities, Current 8.42M USD +121%
Contract with Customer, Liability, Current 2.14M USD -13.3%
Liabilities, Current 13.6M USD +81.4%
Contract with Customer, Liability, Noncurrent 336K USD -54%
Operating Lease, Liability, Noncurrent 610K USD -51.9%
Liabilities 14.6M USD +53.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 14K USD -36.4%
Retained Earnings (Accumulated Deficit) -442M USD -16.4%
Stockholders' Equity Attributable to Parent 66.3M USD -28.6%
Liabilities and Equity 80.9M USD -21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.8M USD -73.4%
Net Cash Provided by (Used in) Financing Activities 1.49M USD +1591%
Net Cash Provided by (Used in) Investing Activities -788K USD +85.6%
Common Stock, Shares Authorized 325M shares 0%
Common Stock, Shares, Issued 38.9M shares +43.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.1M USD -11.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 6K USD
Deferred Tax Assets, Valuation Allowance 77.7M USD +28.4%
Deferred Tax Assets, Gross 77.7M USD +28.4%
Operating Lease, Liability 1.51M USD -28.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -62.2M USD -57.4%
Lessee, Operating Lease, Liability, to be Paid 1.68M USD -31.4%
Property, Plant and Equipment, Gross 1.88M USD +11.3%
Operating Lease, Liability, Current 597K USD +13.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 753K USD +2.87%
Lessee, Operating Lease, Liability, to be Paid, Year One 672K USD -5.35%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 170K USD -48.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 254K USD -66.3%
Deferred Tax Assets, Operating Loss Carryforwards 51.3M USD +10.5%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.4M USD -51.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 254K USD -66.3%
Operating Lease, Payments 223K USD +8.83%
Additional Paid in Capital 512M USD +7.47%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 40K USD +17.6%
Deferred Tax Assets, Net of Valuation Allowance 24K USD +20%
Share-based Payment Arrangement, Expense 4.06M USD +22.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%